Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 First-in-human Study of the Safety and Efficacy of IMC-C103C as Single Agent and in Combination With Atezolizumab in HLA-A0201-positive Patients With Advanced MAGE-A4-positive Cancer

Next Previous
Trial Profile

A Phase 1/2 First-in-human Study of the Safety and Efficacy of IMC-C103C as Single Agent and in Combination With Atezolizumab in HLA-A0201-positive Patients With Advanced MAGE-A4-positive Cancer

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 24 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atezolizumab (Primary) ; IMC C103C (Primary)
  • Indications Gastric cancer; Head and neck cancer; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Solid tumours; Squamous cell cancer; Synovial sarcoma; Urogenital cancer
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Immunocore

Most Recent Events

  • 29 Jan 2024 Status changed from active, no longer recruiting to discontinued (The Sponsor terminated the study and there is no further enrollment. Endpoints will not beassessed for this trial).
  • 27 Sep 2023 Planned End Date changed from 1 Jul 2025 to 1 Feb 2024.
  • 27 Sep 2023 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top